← GLP-1 receptor agonists × glycemic control

TrialJournal of diabetes investigation2016

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.

Yutaka Seino et al.PubMed ↗Full text ↗Publisher ↗

  • Liraglutide plus insulinlooks good hereHigher long-term blood sugar, lower long-term blood sugar, lower insulin dose after 36 weeks.Randomised, small.

What the trial testedrandomised · 257 people · 2016

Randomised vs insulin monotherapy (placebo)

Probably raised long-term blood sugar

51×17× to 154×

liraglutide plus insulin vs insulin monotherapy (placebo)

Bigger than almost all for glycemic control

As reported

OR 50.57, 95% CI 16.6–154 · the paper's word: achieved a glycosylated hemoglobin target of <7.0% (<53 mmol/mol) at week 16

Not counted

Probably lowered long-term blood sugar

−1.30percentage points−1.47 to −1.13

liraglutide plus insulin vs insulin monotherapy

As reported

difference −1.30 %, 95% CI −1.47 to −1.13 · the paper's word: glycosylated hemoglobin after 16 weeks

Not counted

Probably lowered insulin dose after 36 weeks

−18%−24% to −10%

liraglutide plus insulin vs insulin monotherapy (placebo)

Bigger than 1 in 10 for glycemic control

As reported

IRR 0.82, 95% CI 0.76–0.90

Who was studied, and how

257people with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide plus insulin
insulin monotherapy

Probably lowered long-term blood sugar−1.30

randomised

The trial randomly assignedassigned by chance

liraglutide plus insulin
insulin monotherapy (placebo)

Probably raised long-term blood sugar51×

Probably lowered insulin dose after 36 weeks−18%

randomised

the abstract, start to end

… hemoglobin after 16 weeks of -1.30% (-14 mmol/mol; 95% confidence …

… at week 16 (estimated odds ratio 50.57; 95% confidence interval 16.59 …

… the placebo (estimated treatment ratio: 0.82 [95% confidence interval …

← favours treatmentfavours comparator →
could be chance
Glycosylated hemoglobin after 16 weeksliraglutide plus insulin vs insulin monotherapy
−1.30−1.47 to −1.13
Achieved a glycosylated hemoglobin target of <7.0% (<53 mmol/mol) at week 16liraglutide plus insulin vs insulin monotherapy (placebo)
OR 50.5716.6–154
Insulin dose after 36 weeksliraglutide plus insulin vs insulin monotherapy (placebo)
IRR 0.820.76–0.90
GLP-1 receptor agonistsInsulinGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it

Insulin × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 7

33 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it

The trial

NCT01572740phase 3257 enrolled2012
Full record →Abstract, authors, funding and every citing paper · PMID 27182042